The capital market raises for biotech have been just incredible over the past year: a record 60.5% YoY increase. 73 biotech IPOs saw a 34.5% YoY increase in IPO exit size. Step-up multiples from the last private round’s post-money valuation to IPO pre-money valuation spiked as well.
One of the key drivers shaping the industry: new financing structures are emerging as viable options. The traditional angel/VC route is no longer the only option for the substantial capital raises needed for R&D and clinical trials.
If you’re a biotech executive, why are you not running at this market as fast as possible?
PitchBook Q1 2021 Analyst Note – Biotech Went to Work as the World Stayed Home
The biotech & pharma industry was a beacon of hope during an unforgettably difficult year.
Biotech Went to Work as the World Stayed Home
The capital market raises for biotech have been just incredible over the past year: a record 60.5% YoY increase. 73 biotech IPOs saw a 34.5% YoY increase in IPO exit size. Step-up multiples from the last private round’s post-money valuation to IPO pre-money valuation spiked as well.
One of the key drivers shaping the industry: new financing structures are emerging as viable options. The traditional angel/VC route is no longer the only option for the substantial capital raises needed for R&D and clinical trials.
If you’re a biotech executive, why are you not running at this market as fast as possible?
PitchBook Q1 2021 Analyst Note – Biotech Went to Work as the World Stayed Home
The biotech & pharma industry was a beacon of hope during an unforgettably difficult year.